This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Kezar Life Sciences covalent immunoproteasome inhibitor, KZR-616, licensed from Onyx, targets the LMP7 and LMP2 active sites of the immunoproteasome, and…
molecule
1 year ago ●
1 min read
The Genentech XIAP E3-ligase degrader, compound 10, has an interesting mechanism of action, triggering the degradation of its target (XIAP) by…
molecule
1 year ago ●
1 min read
The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of…
molecule
1 year ago ●
1 min read
The Janssen gut-restricted COX-2 inhibitor, compound 10, is a tool compound used to test the hypothesis that gut-restricted COX-2 inhibition would…
molecule
1 year ago ●
1 min read
The GSK BET BD2 inhibitor, GSK852, is one of a series of BD2-targeting compounds published last month by GSK (see a…
molecule
1 year ago ●
1 min read
The BMS AAK1 kinase inhibitor, compound 59, is brain-penetrant and acts on the CNS. The target was identified from a phenotypic…
molecule
1 year ago ●
1 min read
Load More
